The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Abstract
Background and Purpose—: To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg compared with warfarin. Methods—: A Markov decision-analysis model was constructed using data from clinical trials to evaluate lifetime costs and quality-adjusted life-years of novel oral anticoagulants compared with warfarin. The modeled population was a hypothetical cohort of 70-year-old patients with nonvalvular atrial fibrillation, increased risk for stroke (CHADS 2 ≥1), renal creatinine clearance ≥50 mL/min, and no previous contraindications to anticoagulation. The willingness-to-pay threshold was $50 000/quality-adjusted life-years gained. Results—: In the base case, warfarin had the lowest cost of $77 813 (SD, $2223), followed by rivaroxaban 20 mg ($78 738±$1852), dabigatran 150 mg ($82 719±$1959), and apixaban 5 mg ($85 326±$1512). Apixaban 5 mg had the highest quality-adjusted life-years estimate at 8.47 (SD, 0.06), followed by dabigatran 150 mg (8.41±0.07), rivaroxaban 20 mg (8.26±0.06), and warfarin (7.97±0.04). In a Monte Carlo probabilistic sensitivity analysis, apixaban 5 mg, dabigatran 150 mg, rivaroxaban 20 mg, and warfarin were cost-effective in 45.1%, 40%, 14.9%, 0% of the simulations, respectively. Conclusions—: In patients with nonvalvular atrial fibrillation and an increased risk of stroke prophylaxis, apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg were all cost-effective alternatives to warfarin. The cost-effectiveness of novel oral anticoagulantss was dependent on therapy pricing in the United States and neurological events associated with rivaroxaban 20 mg.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Atrial fibrillation as an independent risk factor for stroke: the Framingham study
Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1991) · Stroke · doi:10.1161/01.str.22.8.983 · Cited by 7,388
Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association
Writing Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31823ac046 · Cited by 7,333
Heart Disease and Stroke Statistics—2011 Update: A Report From the American Heart Association
Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Adams, R. J., Berry, J. D., Brown, T. M., Carnethon, M. R., Dai, S., de Simone, G., Ford, E. S., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182009701 · Cited by 6,149
Heidenreich, P. A., Trogdon, J. G., Khavjou, O. A., Butler, J., Dracup, K., Ezekowitz, M. D., Finkelstein, E. A., Hong, Y., Johnston, S. C., Khera, A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820a55f5 · Cited by 3,208
Recommendations of the Panel on Cost-Effectiveness in Health and Medicine
Weinstein, M. C. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540150055031 · Cited by 2,455
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
(1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420130036007 · Cited by 2,071
Glover, J. W. (2010) · Cited by 917
Connolly, S. J., Pogue, J., Eikelboom, J., Flaker, G., Commerford, P., Franzosi, M. G., Healey, J. S., & Yusuf, S. (2008) · Circulation · doi:10.1161/circulationaha.107.750000 · Cited by 870
Handling Uncertainty in Cost-Effectiveness Models
Briggs, A. H. (2000) · PharmacoEconomics · doi:10.2165/00019053-200017050-00006 · Cited by 807
Lifetime Cost of Stroke in the United States
Taylor, T. N., Davis, P. H., Torner, J. C., Holmes, J., Meyer, J. W., & Jacobson, M. F. (1996) · Stroke · doi:10.1161/01.str.27.9.1459 · Cited by 805
United States Life Tables, 2017.
Arias, E., & Xu, J. (2019) · PubMed · Cited by 804
Preference-Based EQ-5D Index Scores for Chronic Conditions in the United States
Sullivan, P. W., & Ghushchyan, V. (2006) · Medical Decision Making · doi:10.1177/0272989x06290495 · Cited by 705
Newly identified events in the RE-LY trial
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1007378 · Cited by 688
Prognosis after initial myocardial infarction: The Framingham study
Kannel, W. B., Sorlie, P., & Mcnamara, P. M. (1979) · The American Journal of Cardiology · doi:10.1016/0002-9149(79)90250-9 · Cited by 569
Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project.
Dennis, M. S., Burn, J. P., Sandercock, P. A., Bamford, J. M., Wade, D. T., & Warlow, C. P. (1993) · Stroke · doi:10.1161/01.str.24.6.796 · Cited by 567
Effect of Study Setting on Anticoagulation Control
van Walraven, C., Jennings, A., Oake, N., Fergusson, D., & Forster, A. J. (2006) · Chest · doi:10.1378/chest.129.5.1155 · Cited by 487
Miniño, A., Murphy, S. L., Xu, J., & Kochanek, K. D. (2011) · PubMed · Cited by 473
Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
Freeman, J. V., Zhu, R. P., Owens, D. K., Garber, A. M., Hutton, D. W., Go, A. S., Wang, P. J., & Turakhia, M. P. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-1-201101040-00289 · Cited by 429
Hart, R. G., Diener, H.-C., Yang, S., Connolly, S. J., Wallentin, L., Reilly, P. A., Ezekowitz, M. D., & Yusuf, S. (2012) · Stroke · doi:10.1161/strokeaha.112.650614 · Cited by 406
A National Catalog of Preference-Based Scores for Chronic Conditions in the United States
Sullivan, P. W., Lawrence, W. F., & Ghushchyan, V. (2005) · Medical Care · doi:10.1097/01.mlr.0000172050.67085.4f · Cited by 388
The Effect of Stroke and Stroke Prophylaxis With Aspirin or Warfarin on Quality of Life
Gage, B. F. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.16.1829 · Cited by 370
Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation
Shah, S. V., & Gage, B. F. (2011) · Circulation · doi:10.1161/circulationaha.110.985655 · Cited by 337
Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin
Eby, C., Milligan, P. E., Banet, G. A., Duncan, J., McLeod, H. L., & Gage, B. F. (2003) · Thrombosis and Haemostasis · doi:10.1160/th03-06-0379 · Cited by 322
United States life tables, 2005.
Arias, E., Rostron, B. L., & Tejada‐Vera, B. (2010) · PubMed · Cited by 250
ROSE, A. J., HYLEK, E. M., OZONOFF, A., ASH, A. S., REISMAN, J. I., & BERLOWITZ, D. R. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03996.x · Cited by 227
Pink, J., Lane, S., Pirmohamed, M., & Hughes, D. A. (2011) · BMJ · doi:10.1136/bmj.d6333 · Cited by 216
A Meta-Analysis of Quality-of-Life Estimates for Stroke
Tengs, T. O., & Lin, T. H. (2003) · PharmacoEconomics · doi:10.2165/00019053-200321030-00004 · Cited by 210
Neumann, P. J., Sandberg, E. A., Bell, C. M., Stone, P. W., & Chapman, R. H. (2000) · Health Affairs · doi:10.1377/hlthaff.19.2.92 · Cited by 180
Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation
O’Brien, C. L. (2005) · JAMA · doi:10.1001/jama.293.6.699 · Cited by 153
Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
Kim, H., Kim, H., Cho, S.-K., Kim, J., Joung, B., & Kim, C. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2018.0220 · Cited by 132
Cost–Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
Lee, S., Anglade, M. W., Pham, D., Pisacane, R., Kluger, J., & Coleman, C. I. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.05.011 · Cited by 130
Leibson, C. L., Hu, T., Brown, R. D., Hass, S., O’Fallon, W. M., & Whisnant, J. P. (1996) · PubMed · Cited by 109
Kamel, H., Johnston, S. C., Easton, J. D., & Kim, A. S. (2012) · Stroke · doi:10.1161/strokeaha.111.641027 · Cited by 108
Executive Summary: Heart Disease and Stroke Statistics—2011 Update
Roger, V. L., Go, A. S., Lloyd‐Jones, D. M., Adams, R. J., Berry, J. D., Brown, T. M., Carnethon, M. R., Dai, S., SIMONE, G. D., Ford, E. S., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820c7a50 · Cited by 107
Long-Term Cost of Stroke Subtypes among Medicare Beneficiaries
Lee, W. C., Christensen, M. C., Joshi, A. V., & Pashos, C. L. (2006) · Cerebrovascular Diseases · doi:10.1159/000096542 · Cited by 95
Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation
Kamel, H., Easton, J. D., Johnston, S. C., & Kim, A. S. (2012) · Neurology · doi:10.1212/wnl.0b013e31826d5fe8 · Cited by 78
Aspirin for the Primary Prevention of Cardiovascular Disease in Women: A Cost-Utility Analysis
Pignone, M. P. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.3.290 · Cited by 77
Cost-Utility of Aspirin and Proton Pump Inhibitors for Primary Prevention
Earnshaw, S., Scheiman, J. M., Fendrick, A. M., McDade, C. L., & Pignone, M. P. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.525 · Cited by 51
Patient Time Requirements for Anticoagulation Therapy with Warfarin
Jonas, D. E., Shilliday, B. B., Laundon, W. R., & Pignone, M. P. (2009) · Medical Decision Making · doi:10.1177/0272989x09343960 · Cited by 29
Cited by
Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges
Chen, A., Stecker, E., & A. Warden, B. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.017559 · Cited by 666
Mega, J. L., & Simon, T. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60243-4 · Cited by 284
Direct oral anticoagulants: analysis of worldwide use and popularity using Google trends
Lippi, G., Mattiuzzi, C., Cervellin, G., & Favaloro, E. J. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.65 · Cited by 91
Lanitis, T., Leipold, R., Hamilton, M., Rublee, D., Quon, P., Browne, C., & Cohen, A. T. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.01.020 · Cited by 23
Metadata
- Authors
- Harrington, A. R., Armstrong, E. P., Nolan, P. E., & Malone, D. C.
- Venue
- Stroke
- Published
- 2013-06
- Volume
- 44
- Issue
- 6
- Pages
- 1676-1681
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2107424955
- Cited by
- 259
- References
- 43
- FWCI
- 32.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.